Grandal Beatriz, Aljehani Ashwaq, Dumas Elise, Daoud Eric, Jochum Floriane, Gougis Paul, Hotton Judicaël, Lemoine Amélie, Michel Sophie, Laas Enora, Laé Marick, Pierga Jean-Yves, Alaoui Ismaili Khaoula, Lerebours Florence, Reyal Fabien, Hamy Anne Sophie
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France.
Department of Surgical Oncology, Institut Curie, University Paris, 75005 Paris, France.
Cancers (Basel). 2022 Jun 23;14(13):3080. doi: 10.3390/cancers14133080.
Breast cancer (BC) is the most common cancer in women worldwide. Neoadjuvant chemotherapy (NAC) makes it possible to monitor in vivo response to treatment. Several studies have investigated the impact of the seasons on the incidence and detection of BC, on tumor composition, and on the prognosis of BC. However, no evidence is available on their association with immune infiltration and the response to treatment. The objective of this study was to analyze pre- and post-NAC immune infiltration as assessed by TIL levels, the response to treatment as assessed by pathological complete response (pCR) rates, and oncological outcomes as assessed by relapse-free survival (RFS) or overall survival (OS) according to the seasonality of BC diagnoses in a clinical cohort of patients treated with neoadjuvant chemotherapy. Out of 1199 patients, the repartition of the season at BC diagnosis showed that 27.2% were diagnosed in fall, 25.4% in winter, 24% in spring, and 23.4% in summer. Baseline patient and tumor characteristics, including notable pre-NAC TIL levels, were not significantly different in terms of the season of BC diagnosis. Similarly, the pCR rates were not different. No association for oncological outcome was identified. Our data do not support the idea that the seasonality of diagnoses has a major impact on the natural history of BC treated with NAC.
乳腺癌（BC）是全球女性中最常见的癌症。新辅助化疗（NAC）使得监测体内对治疗的反应成为可能。多项研究调查了季节对BC发病率、检测、肿瘤构成以及BC预后的影响。然而，关于它们与免疫浸润及治疗反应之间的关联尚无证据。本研究的目的是，在接受新辅助化疗的临床队列患者中，根据BC诊断的季节性，分析通过肿瘤浸润淋巴细胞（TIL）水平评估的NAC前后免疫浸润、通过病理完全缓解（pCR）率评估的治疗反应以及通过无复发生存期（RFS）或总生存期（OS）评估的肿瘤学结局。在1199例患者中，BC诊断时季节分布显示，27.2%在秋季诊断，25.4%在冬季，24%在春季，23.4%在夏季。BC诊断季节方面，包括NAC前显著的TIL水平在内的基线患者和肿瘤特征无显著差异。同样，pCR率也无差异。未发现肿瘤学结局存在关联。我们的数据不支持诊断季节性对接受NAC治疗的BC自然病程有重大影响这一观点。
